---
title: "Alliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285369266.md"
description: "Alliance Global Partners has maintained a Buy rating for Theriva Biologics (TOVX) with a price target of $4.00, according to analyst James Molloy. The current analyst consensus for Theriva is a Moderate Buy, with an average price target of $2.50. Molloy, who also covers other healthcare stocks, has an average return of -22.8% and a 23.64% success rate on his recommendations."
datetime: "2026-05-06T11:38:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285369266.md)
  - [en](https://longbridge.com/en/news/285369266.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285369266.md)
---

# Alliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)

In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Theriva Biologics, with a price target of $4.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Molloy covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Tonix Pharma, and Soligenix. According to TipRanks, Molloy has an average return of \-22.8% and a 23.64% success rate on recommended stocks.

Currently, the analyst consensus on Theriva Biologics is a Moderate Buy with an average price target of $2.50.

### Related Stocks

- [TOVX.US](https://longbridge.com/en/quote/TOVX.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PTHS.US](https://longbridge.com/en/quote/PTHS.US.md)
- [TNXP.US](https://longbridge.com/en/quote/TNXP.US.md)
- [SNGX.US](https://longbridge.com/en/quote/SNGX.US.md)

## Related News & Research

- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO](https://longbridge.com/en/news/287276384.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md)